Related Experiment Video

Updated: May 12, 2026

Standards for Quantitative Metalloproteomic Analysis Using Size Exclusion ICP-MS
09:51

Standards for Quantitative Metalloproteomic Analysis Using Size Exclusion ICP-MS

Published on: April 13, 2016

Obesity and metallothionein

Masao Sato, Takashige Kawakami, Yoshito Kadota

  • 1Faculty of Pharmaceutical Sciences, Tokushima Bunri University, 180 Yamashiro-cho, Tokushima 770-8514, Japan. msato@ph.bunri-u.ac.jp.

Current Pharmaceutical Biotechnology
|April 18, 2013
PubMed
Summary

Metallothionein (MT) is induced in adipose tissue during obesity development and may prevent obesity in female mice. MT might suppress oxidative stress and endoplasmic reticulum stress, offering potential for obesity-related disease treatment.

More Related Videos

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides11:04

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Published on: September 7, 2019

Atomic Absorbance Spectroscopy to Measure Intracellular Zinc Pools in Mammalian Cells13:04

Atomic Absorbance Spectroscopy to Measure Intracellular Zinc Pools in Mammalian Cells

Published on: May 16, 2019

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
The Periodic Table and Organismal Elements00:57

The Periodic Table and Organismal Elements

OverviewElements are the smallest units of matter that cannot be broken down further by chemical processes. There are 118 known elements, but not all of these are naturally-occurring, and fewer still are essential for life. Living matter is composed primarily of carbon, nitrogen, hydrogen, and oxygen, with smaller amounts of other elements like calcium, phosphorus, potassium, and sulfur. Other elements are also necessary for life but only in trace amounts.The Periodic Table Provides Information...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...